BioRegenx,Inc. Completes Merger into FindIt, Inc. and Launches Updated Version of the GlycoCheck HD CapiScope
CHATTANOOGA, TN / ACCESSWIRE / March 13, 2024 / On March 8, 2024, the merger of BioRegenx, Inc. into Atlanta GA/ Findit, Inc. (OTC PINK:FDIT) was cleared by the SEC on January 17, 2024 and went effective with the State of Nevada, along with the …
CHATTANOOGA, TN / ACCESSWIRE / March 13, 2024 / On March 8, 2024, the merger of BioRegenx, Inc. into Atlanta GA/ Findit, Inc. (OTC PINK:FDIT) was cleared by the SEC on January 17, 2024 and went effective with the State of Nevada, along with the name change of the surviving entity to BioRegenx, Inc.. Furthermore, BioRegenx is currently collaborating with FINRA to facilitate a name and symbol change. The company is diligently working towards up-listing to the OTC QB.
In December 2023, BioRegenx's wholly owned subsidiary, Microvascular Health Solutions, Inc. , unveiled the updated version of its pioneering GlycoCheck device, boasting significant hardware and software enhancements. The company commenced sales by fulfilling pre-orders and continues to deliver on new sales, with GlycoCheck system packages priced between $22,000 to $32,000, generating monthly recurring revenue based on usage. Favorable financing options have been secured for GlycoCheck customers, ensuring accessibility and affordability.
Endocalyx Pro, a dietary supplement targeting microvascular capillary health, has achieved remarkable monthly sales figures, demonstrating consistent growth. In 2024, BioRegenx is intensifying its sales and marketing efforts to further boost sales, with GlycoCheck's integration into the market expected to synergistically enhance Endocalyx Pro sales. Moreover, BioRegenx offers a range of supplements through its wholly owned subsidiary, MyBodyRx LLC.
Lesen Sie auch
Following the latest acquisition, DocSun Biomedical Holdings, Inc., a provider of non-contact vital signs monitoring systems, is poised to generate revenue from its distribution agreement, supplying DocSun's AI Engine technology to an electric vehicle manufacturer. Initial revenues will be derived from testing fleets and other vehicles, with commercialization expected to commence in late Q3 or early Q4. Under the terms of the agreement, DocSun receives 40% of the $10 per vehicle license fee, demonstrating promising revenue potential. DocSun's engineers are actively installing new hardware and coding software to expand AI capabilities, positioning the company for future growth opportunities.